Fig. 2

The duration of viral RNA shedding and the titers of specific IgG and IgM in the three groups with comorbidities. A The average duration of viral RNA shedding was lower in the FV and PV groups with comorbidities than in the UV group with comorbidities with no statistical significance (P = 0.07). B The median titer of SARS-CoV-2-specific IgG was significantly higher in the FV group with comorbidities than in the UV group with comorbidities (adjusted P < 0.001). The median titer of SARS-CoV-2-specific IgG was higher in the PV group with comorbidities than in the UV group with comorbidities with no statistical significance (adjusted P = 0.064). C The median titer of SARS-CoV-2-specific IgM was significantly higher in the FV group with comorbidities than in the UV group with comorbidities (adjusted P = 0.005). The median titer of SARS-CoV-2-specific IgM was higher in the PV group with comorbidities than in the UV group with comorbidities, although the difference was not statistically significant (Adjusted P = 0.056). D Cumulative proportion of patients with detectable SARS-CoV-2 RNA by days after the illness onset between the UV, PV, and FV groups with comorbidities. Continuous variables were analyzed by variance analysis or Kruskal‒Wallis test. Kaplan‒Meier survival analysis was used to estimate the cumulative SARS-CoV-2 RNA negativity rate. A P value of less than 0.05 (two-tailed) was considered statistically significant. FV fully vaccinated, PV partially vaccinated, UV unvaccinated, SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2, IQR interquartile range